The Ticker Copaxone Faces New Threat From Pfizer

Perion shares rally on earnings surprise and TASE launches program for small-cap stocks

comments Print
Teva Pharmaceuticals is about to face a big new competitor for its best-selling multiple sclerosis drug, Copaxone.